Press Releases
Latest Press Releases
Cyteir Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Cyteir Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference LEXINGTON, Mass., January 7, 2021 – Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies to treat [...]
Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team
Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team Phase 1/2 study of first-in-class inhibitor of RAD51-mediated homologous recombination advancing to once-daily dosing Secrist, Gengos [...]
Cyteir Therapeutics Secures Additional $40.2 Million in its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor
Cyteir Therapeutics Secures Additional $40.2 Million in its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor New funding brings total Series B raise to $75.2 million Novo [...]
Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors
Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors Novel, targeted, oral drug candidate inhibits DNA-repair protein to induce cell death in multiple [...]
Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases
Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases Lead investor Venrock joined by Celgene, Lightstone and DROIA Markus Renschler, M.D., joins as CEO, from [...]
Cyteir Therapeutics Announces Study Showing RAD51 Modulators Protect Diabetic Mice from Type 1 Diabetes (T1D)
Cyteir Therapeutics Announces Study Showing RAD51 Modulators Protect Diabetic Mice from Type 1 Diabetes (T1D) --Data demonstrates that therapeutic targeting of the AID/RAD51 axis in B cells may block development of T1D by converting [...]